Literature DB >> 7065060

Pharmacokinetics of cefuroxime in pregnancy.

A Philipson, G Stiernstedt.   

Abstract

Most pharmacokinetic studies of antibodies in pregnancy have been carried out at the time of abortion or delivery. Whether such data represent pregnancy as such is not known. The present study compares the pharmacokinetic properties of cefuroxime in seven women during pregnancy, at delivery, and after delivery. After intravenous administration of 750 mg of cefuroxime, levels of the drug in plasma and urine were measured during a period of 8 hours. Levels of cefuroxime in cord plasma and amniotic fluid were registered, as were levels of plasma from the neonates at 6 and 12 hours. Plasma levels were significantly lower during pregnancy than afterward, drug half-life was significantly shorter, and clearance and recovery in urine were significantly higher. Differences, although less consistent, were observed in certain parameters at delivery, as compared to earlier in pregnancy, thus indicating that pharmacokinetic data obtained at delivery may not be typical of pregnancy as such. Passage of cefuroxime across the placenta was well demonstrable in all cases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065060     DOI: 10.1016/s0002-9378(16)32526-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

Review 1.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

2.  Pharmacokinetics of cefuroxime in pregnant patients with preterm premature rupture of the membranes.

Authors:  F J Roumen; P X Bouckaert; H M Cremers; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 3.  Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.

Authors:  André Dallmann; Ibrahim Ince; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

Review 4.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

5.  Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.

Authors:  A Philipson; G Stiernstedt; M Ehrnebo
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 6.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume.

Authors:  D E Holt; N M Fisk; J A Spencer; J de Louvois; R Hurley; D Harvey
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

8.  A survey of pharmacokinetic data from pregnant women.

Authors:  A J Cummings
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

Review 9.  Cephalosporins in urinary tract infection.

Authors:  L O Gentry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.

Authors:  M J Gardner; M Schatz; L Cousins; R Zeiger; E Middleton; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.